+44 20 8123 2220
info@marketpublishers.com

Plasma Fractionation Market - Distribution by Type of Company (In-house Manufacturers and Contract Service Providers), Scale of Operation (Preclinical, Clinical and Commercial), Type of Plasma-derived Therapeutic Products Manufactured (Albumins, Coagulation Factors, Immunoglobulins, Protease Inhibitors and Other Plasma derived Products), Therapeutic Areas of Plasma-derived Products (Hematological Disorders, Hepatic Disorders, Immunological Disorders, Neurological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

https://marketpublishers.com/r/P23215F3F654EN.html
Date: August 2023
Pages: 190
Price: US$ 4,799.00 (Single User License)
ID: P23215F3F654EN

Abstracts

The global plasma fractionation market is estimated to be USD 12.7 billion by 2035 and anticipated to grow at a CAGR of 10% during the forecast period 2023-2035.

In the past twenty years, the number of people affected by rare diseases has notably risen, now impacting over 410 million individuals globally with chronic disorders. This surge in cases has led to a greater need for plasma-derived therapies, which have shown significant effectiveness in treating these conditions. Meeting this growing demand requires a consistent and strong supply of blood plasma. Currently, the United

+44 20 8123 2220
info@marketpublishers.com

States is a central hub for plasma donation centers, housing around 80% of the world's facilities dedicated to plasma donation. Impressively, this country contributes over 70% of the plasma used by plasma fractionators to produce these therapies. Plasma fractionation is vital in separating and refining essential components within blood plasma, such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These refined blood plasma components form the basis for developing therapeutic treatments.

A recent development in April 2023 involved the approval of HYQVIA, a recombinant immunoglobulin, for expanded use in treating primary immunodeficiency in children aged 2 to 16 years. Plasma-derived therapies are crucial in saving lives, especially for those dealing with rare and complex diseases globally. Recognizing the growing need for these critical medicines, ongoing advancements in blood plasma fractionation and manufacturing technology are expected to ensure timely access for those in need in the future. This progress will be instrumental in meeting the increasing demand for plasma-derived therapies amid the rising prevalence of rare and complex diseases.

Report Coverage

The report investigates the plasma fractionation market across several parameters: type of company, scale of operation, type of plasma-derived therapeutic products manufactured, therapeutic areas of plasma-derived products and key geographical regions

It assesses market growth influencers such as drivers, restraints, opportunities, and challenges, analyzing their impact.

Evaluation of market advantages and obstacles is provided, along with insights into the competitive landscape for key market players.

Revenue forecasts for market segments are detailed across four major regions.

An executive summary encapsulates research insights on the current status and anticipated future trends in the plasma fractionation market, covering its components, collection and screening processes, applications, challenges, and the role of third-party service providers. The summary delves into future prospects in this domain.

A comprehensive evaluation of the plasma fractionation market landscape

+44 20 8123 2220
info@marketpublishers.com

involves analyzing companies based on criteria such as establishment year, workforce size, headquarters location, business type (in-house manufacturers, contract service providers), site of fractionation and collection facilities, patented technology presence, additional capabilities (formulation, testing), operational scale, manufactured plasma-derived therapeutic products, therapeutic areas targeted, and end-user demographics.

A meticulous competitive analysis focuses on plasma fractionation companies across North America, Europe, Asia-Pacific, and other regions. Companies are categorized by type (in-house manufacturers, combined manufacturers, service providers) and evaluated based on parameters including experience, facility accreditations, plasma collection infrastructure, proprietary technologies, product portfolios, operational scale, therapeutic focus, and target consumer base.

Detailed tabular profiles of key plasma fractionation companies across North America, Europe, and Asia-Pacific are presented, encompassing company overviews, financial data (if available), fractionation portfolios, recent developments, and anticipated future trajectories.

An analysis of recent partnerships and collaborations in plasma fractionation, plasma-derived therapies, and associated technologies post-2018. Parameters include partnership types, objectives (collection, purification, fractionation), plasma-derived product categories, partner types (industry, non-industry), and active participants, with regional distribution of engaged companies.

An in-depth examination of expansions undertaken by diverse companies since 2018 to enhance their plasma fractionation capabilities. Analysis includes expansion timelines, types (capacity, new facilities), facility categorization (collection, fractionation), facility locations, manufactured plasma-derived products, and key contributors.

Detailed analysis of global fractionation capacity based on publicly available information and insights from primary and secondary research. This examination highlights capacity distribution based on company size, manufactured plasma-derived therapeutic products, operational scale, and geographic regions (North America, Europe, Asia-Pacific, and others).

Key Market Companies

+44 20 8123 2220
info@marketpublishers.com

Baxter

Grifols

Kedrion

Octapharma

CSL

Takeda Pharmaceutical

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

7. PARTNERSHIPS AND COLLABORATIONS

+44 20 8123 2220
info@marketpublishers.com

8. RECENT EXPANSIONS

9. CAPACITY ANALYSIS

10. MARKET SIZING AND OPPURTUNITY ANALYSIS

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Plasma Fractionation Market - Distribution by Type of Company (In-house Manufacturers and Contract Service Providers), Scale of Operation (Preclinical, Clinical and Commercial), Type of Plasma-derived Therapeutic Products Manufactured (Albumins, Coagulation Factors, Immunoglobulins, Protease Inhibitors and Other Plasma derived Products), Therapeutic Areas of Plasma-derived Products (Hematological Disorders, Hepatic Disorders, Immunological Disorders, Neurological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Product link: https://marketpublishers.com/r/P23215F3F654EN.html

Price: US$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P23215F3F654EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

+44 20 8123 2220
info@marketpublishers.com

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970